A carregar...

Annual Bleeding Rates: Pitfalls of Clinical Trial Outcomes in Hemophilia Patients

Emerging treatment options for hemophilia, including gene therapy, modified factor products, antibody‐based products, and other nonreplacement therapies, are in development or on their way to marketing authorization. For proof of efficacy, annual bleeding rates (ABRs) have become an increasingly imp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Sci
Main Authors: Keipert, Christine, Müller‐Olling, Mirco, Gauly, Franca, Arras‐Reiter, Cornelia, Hilger, Anneliese
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7719362/
https://ncbi.nlm.nih.gov/pubmed/32472976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12794
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!